Name

LINDIS Biotech

Legal name

LINDIS Biotech GmbH

Website

https://lindisbiotech.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Martinsried

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing and Commercialization Royalties: LINDIS Biotech grants exclusive licensing rights to commercialize its products. Under the November 2024 agreement with Pharmanovia, Pharmanovia received exclusive rights to bring Catumaxomab to market and lead all launch activities across Europe. LINDIS receives licensing fees and potentially milestone payments and royalties from product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

LINDIS Biotech develops Triomab® antibodies, a class of T-cell engaging bispecific trifunctional antibodies for cancer immunotherapy. The company is advancing a pipeline of clinical-stage candidates including Catumaxomab (KORJUNY) for malignant ascites and bladder cancer, Ertumaxomab for HER2-positive tumors, FBTA05/Lymphomun for B-cell malignancies, and Ektomun for neuroblastoma and melanoma. The company operates as a lean R&D organization that commercializes its products through licensing and co-development partnerships with pharmaceutical companies.

Product overview

LINDIS Biotech is a clinical-stage biopharmaceutical company developing a portfolio of T-cell engaging trifunctional bispecific antibodies based on the proprietary Triomab® platform. The company's lead product is Catumaxomab (brand names Removab®/KORJUNY®), which was the first T-cell engaging multi-specific antibody worldwide to receive EU approval. The pipeline includes three clinical-stage candidates: Ertumaxomab (anti-HER2, for breast cancer), FBTA05/Lymphomun (anti-CD20, for B-cell malignancies), and Ektomun (anti-GD2, for neuroblastoma/melanoma). The Triomab® platform enables simultaneous targeting of tumor antigens and immune system activation, creating a unique therapeutic vaccine effect alongside direct tumor cell killing.

Differentiator

Problem solved

Functional benefit

Products and services

• Catumaxomab (KORJUNY/Removab) Trifunctional bispecific anti-EpCAM × anti-CD3 antibody for intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas. Also being developed for intravesical treatment of high-risk non-muscle invasive bladder cancer (HR-NMIBC). Licensed to Pharmanovia for European commercialization.
• Ertumaxomab Trifunctional anti-HER2 × anti-CD3 antibody for treatment of HER2-positive breast cancer and other solid tumors. Activates T-cells and Fc-gamma receptor positive immune cells against HER2-expressing tumor cells.
• FBTA05 (Lymphomun) Trifunctional anti-CD20 × anti-CD3 antibody for treatment of CD20-positive B-cell malignancies including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and non-Hodgkin lymphoma (NHL). Effective even with low CD20 expression levels.
• Ektomun GD2-directed trifunctional bispecific antibody for treatment of GD2-positive malignancies including neuroblastoma and malignant melanoma. Activates T-cells and accessory immune cells against GD2-expressing tumor cells.
• Triomab Platform Technology Proprietary technology platform for developing trifunctional bispecific T-cell engaging antibodies. Combines direct tumor-cell killing with an anti-tumor vaccine effect by linking tumor-associated antigens with CD3 on T-cells and Fc-gamma receptor positive accessory immune cells (macrophages, DCs, NK cells). Available for license or co-development partnerships.

Quantifiable outcome

• Patients receiving KORJUNY had a four-fold increase in puncture-free survival over therapy with puncture alone in Phase II/III study (IP-REM-AC-01)
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and strategic.

• PharmanoviacoreOEM/ Whitelabel/ Licensing Partner · 19 November 2024LINDIS Biotech granted Pharmanovia exclusive rights to commercialize Catumaxomab (brand name KORJUNY) for treatment of malignant ascites across Europe. Pharmanovia leads all activities to launch the product. The partnership includes marketing authorization activities and future commercial distribution in EU member states plus Iceland, Liechtenstein, and Norway. Alira Health acted as exclusive transaction advisor to LINDIS Biotech.
• Linton PharmcoreStrategic or Co-development PartnerStrategic partner in Guangzhou, China for the development of Triomab and Fleximab antibodies in Asia. Linton Pharm serves as LINDIS Biotech's strategic partner for Asian market development of the antibody platform technology.
• Trion Research GmbHcoreStrategic or Co-development PartnerResearch partner located in Martinsried, Munich (IZB Innovation Center) for discovery and development of new drug candidates. TRION Research is co-founded by Dr. Horst Lindhofer and serves as the research engine for new Triomab antibody development.
• University Hospital LeipzigstrategicStrategic or Co-development PartnerCollaboration with Institute for Transfusion Medicine (Dr. med. Raymund Buhmann) for development of Triomab-armed immune effector cells for treatment of hematological and oncological neoplasia.
• Helmholtz-Zentrum MünchenstrategicStrategic or Co-development PartnerCollaboration with German research centre for environmental health (Prof. Dr. Reinhard Zeidler, Abteilung Genvektoren, Deutsches Zentrum für Infektionsforschung) on diverse translational research projects.
• Charité BerlinstrategicStrategic or Co-development PartnerCollaboration with Department of Pediatrics, Division of Oncology and Hematology (PD Dr. med. Annette Künkele) for non-clinical development of GD2-specific Triomab antibodies (Ektomun) for neuroblastoma treatment.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Amgen: Amgen developed the BiTE (bispecific T-cell engager) platform, including Blincyto (blinatumomab), which is the most commercially validated direct competitor to LINDIS's Triomab bispecific antibody approach. Both companies target T-cell engagement against hematologic and solid tumor antigens.
• Roche: Roche has multiple bispecific antibodies including Hemlibra, mosunetuzumab, and glofitamab targeting hematologic malignancies (CD20, CD19, Factor IXa). Roche is a broad incumbent competing for the same patient populations LINDIS targets with FBTA05/Lymphomun (anti-CD20).
• AstraZeneca: AstraZeneca has invested heavily in bispecific T-cell engagers and antibody-drug conjugates including Datroway, Enhertu, and Trastuzumab deruxtecan. It competes with LINDIS in HER2-positive breast cancer (Ertumaxomab) and broader immuno-oncology indications.

Direct peers

• Genmab: Genmab's DuoBody platform is a leading bispecific antibody technology with multiple partnered programs. Genmab represents a direct technology competitor to LINDIS's Triomab platform in the bispecific antibody space and has the capital and partnerships to compete for similar oncology indications.
• Y-mAbs Therapeutics: Y-mAbs commercializes Danyelza (naxitamab), an anti-GD2 monoclonal antibody for neuroblastoma, directly competing with LINDIS's Ektomun (anti-GD2 trifunctional) program. Both companies target the same GD2-positive neuroblastoma patient population with similar mechanisms.
• MacroGenics: MacroGenics develops bispecific DART molecules and has multiple clinical-stage oncology candidates including margetuximab and enoblituzumab. It competes with LINDIS in both HER2-targeted therapy (Ertumaxomab) and broader bispecific antibody oncology indications.
• Xencor: Xencor's XmAb bispecific antibody platform has produced multiple clinical-stage oncology candidates, including CD20 x CD3 bispecifics that directly compete with LINDIS's FBTA05/Lymphomun. Both companies are similarly sized clinical-stage bispecific antibody developers.
• Zymeworks: Zymeworks develops Azymetric and Zanidatamab-based bispecific antibodies for oncology including HER2-targeted therapies. It is a similarly sized clinical-stage peer competing in HER2-positive solid tumors where LINDIS's Ertumaxomab is positioned.

Emerging players

• Molecular Partners: Molecular Partners develops DARPin-based multi-specific therapeutics for oncology with clinical candidates including MP0310 and MP0317. It represents an emerging competitor in the multi-specific oncology antibody space with comparable company size to LINDIS.
• CatalYm: CatalYm is a German clinical-stage immuno-oncology company developing antibodies targeting GDF-15. Like LINDIS, it is based in Germany (Martinsried/Munich biotech cluster), shares the lean clinical-stage biotech profile, and pursues novel immuno-oncology mechanisms in solid tumors.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LINDIS Biotech